Bluechiip Limited Stock Market Press Releases and Company Profile
December 2018 Quarterly Report
December 2018 Quarterly Report

Melbourne, Jan 30, 2019 AEST (ABN Newswire) - Bluechiip Limited (Bluechiip or the Company) (googlechartASX:BCT) today released its quarterly cash flow report for the period ended 31 December 2018.

ACTIVITIES REPORT FOR THE QUARTER ENDED 31 DECEMBER 2018

Highlights during the quarter

- Commenced monthly delivery of readers and chips to Labcon with sales revenue of $117k in the December quarter 2018 following Labcon's updated US$11.9m development and supply agreement in prior quarter.

- Scaling to meet customer orders, including to Labcon.

- Continued expansion of the pipeline with 32 developer kits and agreements in market.

- Fully repaid $0.6m R&D Advance Facility.

- Cash balance stands at $5.670m as at 31 December 2018 with no borrowings.

Business Progress Update

In December the first of our ongoing monthly deliveries under the revised agreement with Labcon North America's (Labcon) purchase orders was made. This was following the updated development and supply agreement on 29 August 2018 for a three-year term to supply chips, readers, software and engineering services worth US$11.9m ($15.9m).

Bluechiip has progressed transfer to production of the multi vial reader and hand-held reader and continued scaling the Bluechiip supply chain. With Labcon's Coldpoint Bluechiip Enabled Range moving into full production, deliveries are expected to accelerate over the coming 2 quarters.

Bluechiip continued to progress and pursue partnerships with 32 developer kits and agreements with potential partners in North America, Europe and Asia increasing our pipeline of opportunities.

To view the full report, please visit:
http://abnnewswire.net/lnk/5C09T6U2


About Bluechiip Limited

Bluechiip Ltd ASX BCTBluechiip Ltd (ASX:BCT) understands that every sample - stem cells, blood, eggs, sperm and other biospecimens - is critical, so our objective is to manage each one with optimal quality in the most efficient way. Bluechiip's advanced management solution is the only one that provides sample temperature with ID in cryogenic environments to. Most importantly, this delivers confidence in every sample.

Bluechiip's unique patented technology is a MEMS-based wireless tracking solution that contains no electronics. It represents a generational change from current tracking methods such as labels (hand-written and pre-printed), barcodes (linear and 2D), and Radio Frequency Identification. Bluechiip tags are either embedded or manufactured into storage products such as vials or bags. Each product can be easily identified, and critical information such as sample temperature, is detected by readers and stored in the Bluechiip software. In addition to functioning in extreme temperatures, the Bluechiip(R) Advanced Sample management solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.

Bluechiip's technology has applications in healthcare, including in cryogenic storage facilities (biobanks and biorepositories), pathology, clinical trials and forensics. Other key markets include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.

Bluechiip: Delivering confidence in every sample.

 

https://twitter.com/bluechiip https://www.youtube.com/channel/UCaVcyO4O2oJ_9fLdMs6JIyQ https://www.linkedin.com/company/bluechiip-limited abnnewswire.com 


Contact

Corporate enquiries
Andrew McLellan
Managing Director - CEO
Ph: +61-457-823-470
andrew.mclellan@bluechiip.com

Media
Richard Allen
Ph: +61-3-9915-6341
Oxygen Financial PR
richard@oxygenpr.com.au



ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 6) (Last 30 Days: 32) (Since Published: 3748)